|
|
 |
Publications
Displaying 781 through 800 of 1537 items.
« Previous
Page
1 10 20 30
40
41 42 43 44 45 46 47 48 49 50 60 70 77
Next »
[Show All]
| 2006 |
Canh, D.G., D. Whittington, L.T.K. Thoa, N. Utomo, N.T. Hoa, C. Poulos, D.T.D. Thuy, D. Kim, A. Nyamete, and C. Acosta. (2006). "Household demand for typhoid fever vaccines in Hue, Vietnam." Health Policy and Planning, 21(3):241-255.
|
Candrilli, S., and J. Mauskopf. (2006). "How much does a day in the hospital cost?." Value in Health, 9(3):A56-A56.
|
Kolotkin, R.L., R.D. Crosby, and A.A. Allshouse. (2006). "Impact of abdominal obesity on quality of life." Value in Health, 9(3):A91-A92.
|
Mauskopf, J., G.E. Simon, C. Nimsch, and A. yyar-Krishnan. (2006). "Measurement of utility losses in depression." Value in Health, 9(3):A79-A79.
|
Varas-Lorenzo, C., A.M. Rueda de Castro, A. Maguire, and M. Miret. (2006). "Prevalence of glucose metabolism abnormalities and cardiovascular co-morbidity in the US elderly adult population." Pharmacoepidemiology and Drug Safety, 15(5):317-326.
Purpose To estimate the prevalence of glucose metabolism abnormalities, including diabetes, and its associated cardiovascular risk factors and co-morbidity in the US elderly population. Methods...
Full Abstract »
|
Johnson, F.R., G. Van Houtven, C. Mansfield, S. Ozdemir, and D.W. Miller. (2006). "Quantifying patients' risk-benefit tradeoff preferences: A conceptual and empirical comparison of methods." Value in Health, 9(3):A5-A5.
|
Earnshaw, S.R., M.R. Wilson, and A.V. Joshi. (2006). "Short-term cost-effectiveness of recombinant activated factor VII in the treatment of intracerebral hemorrhage." Value in Health, 9(3):A8-A8.
|
Earnshaw, S.R., C.N. Graham, M.M. Amonkar, and C.E. Barr. (2006). "The cost-effectiveness of ibandronate in the treatment of postmenopausal osteoporosis in the US." Value in Health, 9(3):A163-A163.
|
McCrink, L., S. Beard, and T.K. Le. (2006). "The relationship between health related quality of life (HRQOL) and pain response in patients with diabetic peripheral neuropathic pain (DPNP)." Value in Health, 9(3):A41-A41.
|
Luce, B.R., J. Mauskopf, F.A. Sloan, J. Ostermann, and C. Paramore. (2006). "The return on investment in health care: From 1980 to 2000." Value in Health, 9(3):146-156.
OBJECTIVE: To estimate the return on US investment (ROI) in overall health as well as four specific conditions. METHODS: The study utilized three distinct approaches to "triangulate" the evidence as...
Full Abstract »
|
Santanello, N.C., C.J. DeMuro-Mercon, S.R. Shah, E.J. Schenkel, P.H. Ratner, J.M. Norquist, and G. Philip. (2006). "Validation of the nighttime symptoms score as a clinically relevant measure of allergic rhinitis." Allergy and Asthma Proceedings, 27(3):231-239.
|
Johnson, F.R., S. Ozdemir, C. Mansfield, B.E. Sands, C.A. Siegel, S.L. Hass, D.W. Miller, and T.J. White. (2006). "Weighing treatment benefits against treatment risks: Crohn's disease patients' willingness to accept risk-benefit tradeoffs." Value in Health, 9(3):A50-A50.
|
Mladsi, D., and A. Barrett. (2006). "Winners and losers: Patterns in economic evaluations of anti-epileptic drugs." Value in Health, 9(3):A83-A83.
|
Macmahon, B., and K.J. Rothman. (2006). "Anencephaly and twins." Prenatal Diagnosis, 26(4):380-381.
|
Bala, M.V., and J.A. Mauskopf. (2006). "Optimal assignment of treatments to health states using a Markov decision model: An introduction to basic concepts." Pharmacoeconomics, 24(4):345-354.
Assessing the cost effectiveness of a new health intervention often requires modelling to estimate the impact of the intervention on cost, survival and quality of life over the lifetime of a cohort...
Full Abstract »
|
Mangel, A.W.. (2006). "Personal view: adequate relief as a primary endpoint in irritable bowel syndrome." Alimentary Pharmacology and Therapeutics, 23(7):879-881.
The success of a clinical trial is judged by achieving statistical and clinical significance on the primary endpoint. This is particularly relevant in those trials that are initiated to achieve...
Full Abstract »
|
Pignone, M., S. Earnshaw, J.A. Tice, and M.J. Pletcher. (2006). "Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis." Annals of Internal Medicine, 144(5):326-336.
BACKGROUND: Aspirin and statins are both effective for primary prevention of coronary heart disease (CHD), but their combined use has not been well studied. OBJECTIVE: To perform a cost-utility...
Full Abstract »
|
Johnson, F.R., A.B. Hauber, D. Osoba, M.A. Hsu, J. Coombs, and C. Copley-Merriman. (2006). "Are Chemotherapy Patients' HRQoL Importance Weights Consistent with Linear Scoring Rules? A Stated-choice Approach." Quality of Life Research, 15(2):285-298.
Objective: To compare a linear scoring rule with the subjective importance of different domain and symptom levels of the European Organization for Research and Treatment of Cancer Quality of Life...
Full Abstract »
|
Cohen, A.T., C. Hirst, B. Sherrill, P. Holmes, and D. Fidan. (2006). "Authors' reply: Meta-analysis of trials comparing ximelagatran with low molecular weight heparin for prevention of venous thromboembolism after major orthopaedic surgery (Br J Surg 2005; 92 : 1335-1344)." British Journal of Surgery, 93(3):375-376.
|
Bartlett, J.A., J.J. Buda, B. von Scheele, J.A. Mauskopf, E.A. Davis, R. Elston, M.S. King, and E.R. Lanier. (2006). "Minimizing resistance consequences after virologic failure on initial combination therapy: A systematic overview." JAIDS: Journal of Acquired Immune Deficiency Syndromes, 41(3):323-331.
Objective: To identify optimal first-line therapies based on the rate of virologic success (VS) and the preservation of future treatment options in antiretroviral therapy (ART)-naive subjects....
Full Abstract »
|
Displaying 781 through 800 of 1537 items.
« Previous
Page
1 10 20 30
40
41 42 43 44 45 46 47 48 49 50 60 70 77
Next »
[Show All]
|
